White DE - Search Results

1

Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer.

Belldegrun A, Webb DE, Austin HA 3rd, Steinberg SM, White DE, Linehan WM, Rosenberg SA. Belldegrun A, et al. Among authors: white de. Ann Intern Med. 1987 Jun;106(6):817-22. doi: 10.7326/0003-4819-106-6-817. Ann Intern Med. 1987. PMID: 3495213

2

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.

Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE. Rosenberg SA, et al. Among authors: white de. Ann Surg. 1989 Oct;210(4):474-84; discussion 484-5. doi: 10.1097/00000658-198910000-00008. Ann Surg. 1989. PMID: 2679456 Free PMC article.

3

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.

Rosenberg SA, Lotze MT, Yang JC, Linehan WM, Seipp C, Calabro S, Karp SE, Sherry RM, Steinberg S, White DE. Rosenberg SA, et al. Among authors: white de. J Clin Oncol. 1989 Dec;7(12):1863-74. doi: 10.1200/JCO.1989.7.12.1863. J Clin Oncol. 1989. PMID: 2685181 Clinical Trial.

4

Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients.

Ettinghausen SE, Moore JG, White DE, Platanias L, Young NS, Rosenberg SA. Ettinghausen SE, et al. Among authors: white de. Blood. 1987 Jun;69(6):1654-60. Blood. 1987. PMID: 3495302 Free article.

5

Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone.

Krouse RS, Royal RE, Heywood G, Weintraub BD, White DE, Steinberg SM, Rosenberg SA, Schwartzentruber DJ. Krouse RS, et al. Among authors: white de. J Immunother Emphasis Tumor Immunol. 1995 Nov;18(4):272-8. doi: 10.1097/00002371-199511000-00008. J Immunother Emphasis Tumor Immunol. 1995. PMID: 8680655

6

Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.

Rosenberg SA, White DE. Rosenberg SA, et al. Among authors: white de. J Immunother Emphasis Tumor Immunol. 1996 Jan;19(1):81-4. J Immunother Emphasis Tumor Immunol. 1996. PMID: 8859727

7

Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.

Rosenberg SA, Yang JC, White DE, Steinberg SM. Rosenberg SA, et al. Among authors: white de. Ann Surg. 1998 Sep;228(3):307-19. doi: 10.1097/00000658-199809000-00004. Ann Surg. 1998. PMID: 9742914 Free PMC article. Clinical Trial.

8

Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place.

Wagner JR, Walther MM, Linehan WM, White DE, Rosenberg SA, Yang JC. Wagner JR, et al. Among authors: white de. J Urol. 1999 Jul;162(1):43-5. doi: 10.1097/00005392-199907000-00011. J Urol. 1999. PMID: 10379736

9

Decreased tolerance to interleukin-2 with repeated courses of therapy in patients with metastatic melanoma or renal cell cancer.

Marroquin CE, White DE, Steinberg SM, Rosenberg SA, Schwartzentruber DJ. Marroquin CE, et al. Among authors: white de. J Immunother. 2000 May-Jun;23(3):387-92. doi: 10.1097/00002371-200005000-00012. J Immunother. 2000. PMID: 10838668

10

Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients.

Fisher B, Keenan AM, Garra BS, Steinberg SM, White DE, DiBisceglie AM, Hoofnagle JH, Yolles P, Rosenberg SA, Lotze MT. Fisher B, et al. Among authors: white de. J Clin Oncol. 1989 Dec;7(12):1852-62. doi: 10.1200/JCO.1989.7.12.1852. J Clin Oncol. 1989. PMID: 2585024

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

208 results

Search Page

Filters